Brands With Heart: Small Food Brands Score Big with 7-Eleven

 
Convenience store chain 7-Eleven recently completed its fourth Brands With Heart program, a competition among up-and-coming brands to earn a spot among the store’s shelves. Not only is Brands With Heart a great way to stock the 7-Eleven shelves with a wider variety of products, but it paid tribute and drew attention to some great brands that are less well-known. The chain has its own private label brand for food and beverage, but still partners with brands across the country.

Jeff Lenard, VP of Strategic Industry Initiatives for the National Association of Convenience Stores, explains the “hybrid model” 7-Eleven subscribes to, and why it benefits convenience stores across the country.

Jeff’s Thoughts

“What 7-11 in a lot of convenience retailers are doing with these types of programs are, thinking of it more like a hybrid between their own products when you have a private label and what they might have when they’re working with traditional vendors, somewhat of a hybrid, where these are different types of brands that you may only be able to find in these stores.

The second point is looking at the sense of higher purpose and why does your beverage, why does your snack taste better than the competitions? When you tell that story around the sense of purpose, you’re able to differentiate yourself, and that’s something that we’re increasingly seeing convenience retailers do to differentiate themselves in the competition because when you’re in the convenience space and everyone is in the convenience space. You need to find a way to differentiate yourself. If the only other ways are based on location or based on price.”

Follow us on social media for the latest updates in B2B!

Image

Latest

cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More
organoids
Growing the Future of Cancer Research: Inside the Promise of Organoids
April 19, 2025

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…

Read More
Immuno-Oncology
Shaping the Future of Cancer Care Through Immuno-Oncology
April 19, 2025

In the ever-evolving world of cancer treatment, immuno-oncology (IO) continues to stand at the forefront of innovation. With recent FDA approvals for TIL therapies and bispecific antibodies, and new developments in CAR-T technologies, the field is rapidly expanding into combination-based strategies that integrate with standard care. Researchers are also exploring how to overcome challenges posed…

Read More